Back

Cardiovascular–kidney–metabolic risk stratification and cardiorenal outcomes with SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes: a global federated network study

30 August 2026 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: Cardiorenal metabolic disease mechanisms and treatment Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Chen Wang

Institute of Life Course and Medical Sciences, Liverpool (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Abdominal obesity leads to earlier and higher CKM syndrome risk than general obesity: a cross-sectional NHANES study
Doctor Q. Tai (Xi'an, CN)
Abstract
Presentation thumbnail
Adiposity and diabetes in Mexican adults: evidence from observational and mendelian randomization analyses of a large prospective study
Doctor L. Friedrichs (Oxford, GB)
Abstract
Presentation thumbnail
Long-term BMI burden, its variability from childhood to adulthood and cardiovascular-kidney-metabolic syndrome in midlife: a 36-year cohort study
Doctor G. Hu (Xi'an, CN)
Abstract
Presentation thumbnail
Proteomic profiling of genetically defined endotypes reveals molecular heterogeneity of obesity
Mr D. Malik (US)
Abstract

Access the full session

Session thumbnail
Cardiorenal metabolic disease mechanisms and treatment

The Event

Event poster

ESC Congress 2026

30 August 2026 11:05 CET
You may be interested in
thumbnail
Congress Presentation
Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
29 June 2021
thumbnail
Congress Presentation
GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany
1 September 2025
thumbnail
Congress Session
Real-world experience from an MDT cardiometabolic clinic
23 June 2023
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources